AU533386B2 - Isolation of membrane proteins from neisseria meningitidis and vaccines containing same - Google Patents

Isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Info

Publication number
AU533386B2
AU533386B2 AU52682/79A AU5268279A AU533386B2 AU 533386 B2 AU533386 B2 AU 533386B2 AU 52682/79 A AU52682/79 A AU 52682/79A AU 5268279 A AU5268279 A AU 5268279A AU 533386 B2 AU533386 B2 AU 533386B2
Authority
AU
Australia
Prior art keywords
isolation
membrane proteins
neisseria meningitidis
containing same
vaccines containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU52682/79A
Other versions
AU5268279A (en
Inventor
Gerhard Guthohrlein
Torsten Bertil Helting
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines GmbH
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of AU5268279A publication Critical patent/AU5268279A/en
Application granted granted Critical
Publication of AU533386B2 publication Critical patent/AU533386B2/en
Assigned to CHIRON BEHRING GMBH & CO. reassignment CHIRON BEHRING GMBH & CO. Alteration of Name(s) in Register under S187 Assignors: BEHRINGWERKE AKTIENGESELLSCHAFT
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Process for the isolation of membrane proteins from Neisseria meningitidis which comprises treating the organism with the aqueous solution of a detergent in a concentration of 0.1 to 2% w/v for 15 minutes to 24 hours, allowing the mixture to stand, optionally with agitation, separating the extract from the bacterial residue and optionally carrying out a further purification.
AU52682/79A 1978-11-11 1979-11-09 Isolation of membrane proteins from neisseria meningitidis and vaccines containing same Ceased AU533386B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19782848965 DE2848965A1 (en) 1978-11-11 1978-11-11 METHOD FOR PRODUCING MEMBRANE PROTEINS FROM NEISSERIA MENINGITIDIS AND VACCINE CONTAINING THEM
DE28489658 1978-11-11

Publications (2)

Publication Number Publication Date
AU5268279A AU5268279A (en) 1980-05-15
AU533386B2 true AU533386B2 (en) 1983-11-24

Family

ID=6054405

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52682/79A Ceased AU533386B2 (en) 1978-11-11 1979-11-09 Isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Country Status (9)

Country Link
EP (1) EP0011243B1 (en)
JP (1) JPS5566519A (en)
AT (1) ATE857T1 (en)
AU (1) AU533386B2 (en)
CA (1) CA1142083A (en)
DE (2) DE2848965A1 (en)
DK (1) DK154841C (en)
ES (1) ES485715A1 (en)
IL (1) IL58673A (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002194A1 (en) * 1982-12-02 1984-06-07 Univ Rockefeller IgA BINDING ANTIBODY
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
PT1079857E (en) 1998-05-29 2007-02-28 Statens Inst For Folkehelse Combination meningitidis b/c vaccines
NZ528254A (en) 1999-05-19 2005-07-29 Chiron S Combined neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
BR0107679A (en) 2000-01-17 2004-07-06 Chiron Spa Outer membrane vesicle (omv) vaccine comprising neisseria meningitidis serum group b outer membrane proteins
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP2481419A3 (en) 2002-08-02 2013-04-10 GlaxoSmithKline Biologicals S.A. Neisserial vaccines
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CU23313A1 (en) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia MÃ0 / 00 METHOD OF OBTAINING COCLEAR STRUCTURES VACCINAL COMPOSITIONS AND ADJUSTS BASED ON COCLEAR STRUCTURES AND THEIR INTERMEDIARIES
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
EP1706481A2 (en) * 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Vaccine
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP5275982B2 (en) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
BRPI0818545A2 (en) 2007-10-19 2017-07-04 Novartis Ag meningococcal vaccine formulations
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP2012512240A (en) 2008-12-17 2012-05-31 ノバルティス アーゲー Meningococcal vaccine containing hemoglobin receptor
ES2658863T3 (en) 2009-06-10 2018-03-12 Glaxosmithkline Biologicals Sa Vaccines containing benzonaphthyridine
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
CN104650241A (en) 2009-08-27 2015-05-27 诺华股份有限公司 Hybrid polypeptides including meningococcal fHBP sequences
JO3257B1 (en) 2009-09-02 2018-09-16 Novartis Ag Compounds and compositions as tlr activity modulators
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CA2776004A1 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
MX2012004850A (en) 2009-10-27 2012-05-22 Novartis Ag Modified meningococcal fhbp polypeptides.
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (en) 2009-12-15 2017-12-26 Novartis Ag homogeneous suspension of immunopotentiation compounds and uses of these
CN102869377A (en) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 Immunogenic composition
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
JP5848748B2 (en) 2010-03-23 2016-01-27 アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ Compounds (cysteine-based lipopeptides) and compositions as TLR2 agonists for use in the treatment of infectious diseases, inflammation, respiratory diseases, etc.
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
CA2861946A1 (en) 2012-02-02 2013-08-08 Novartis Ag Promoters for increased protein expression in meningococcus
ES2750366T3 (en) 2012-03-08 2020-03-25 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
MX357538B (en) 2012-06-14 2018-07-13 Novartis Ag Vaccines for serogroup x meningococcus.
MX2015002717A (en) 2012-09-06 2015-05-15 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p.
CA2882382A1 (en) 2012-09-18 2014-03-27 Novartis Ag Outer membrane vesicles
ES2841378T3 (en) 2014-02-28 2021-07-08 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
WO2018042015A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
MX2021005303A (en) 2018-11-06 2021-07-07 Glaxosmithkline Biologicals Sa Immunogenic compositions.
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202115072D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Also Published As

Publication number Publication date
DE2848965A1 (en) 1980-05-22
DE2962526D1 (en) 1982-05-27
EP0011243B1 (en) 1982-04-14
IL58673A0 (en) 1980-02-29
CA1142083A (en) 1983-03-01
DK475779A (en) 1980-05-12
EP0011243A1 (en) 1980-05-28
DK154841B (en) 1988-12-27
DK154841C (en) 1989-06-05
JPS5566519A (en) 1980-05-20
JPS6350332B2 (en) 1988-10-07
IL58673A (en) 1983-02-23
AU5268279A (en) 1980-05-15
ATE857T1 (en) 1982-04-15
ES485715A1 (en) 1980-05-16

Similar Documents

Publication Publication Date Title
AU533386B2 (en) Isolation of membrane proteins from neisseria meningitidis and vaccines containing same
DE69423383D1 (en) Production and uses of LOS-reduced outer membrane proteins from gram-negative cocci
DE69224124D1 (en) Process for the preparation of dihomo-gamma-linolenic acid and the lipid contained therein
DE69116305D1 (en) Process for the production of trehalulose and isomaltulose
ZA838072B (en) Beta-carbolines,process for their production and pharmaceutical preparations containing them
HUT50863A (en) Amperometric process for quantitative statement of 1,4 dihydronicotinamid adenin dinucleotid /nadh/ in solution
JPS6485086A (en) Protein f for outer membrane of pseudomonas aeruginosa
JPS6452726A (en) Method for removing endotoxin of pertussis, pertussis toxoid and production thereof
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
IN169113B (en)
ES8800275A1 (en) POLYDISPERSED NATIVE PSEUDOMONAS-FLAGELLA (H)-ANTIGENS (FAg) AND METHODS FOR THEIR PREPARATION.
DE3265664D1 (en) Process for the production of a biochemical vaccine against salmonella fevers
DE3366707D1 (en) Preparation of glucose dehydrogenase
JPS57122792A (en) Preparation of cholesterol oxidase
YU45458B (en) Process for obtaining liquid ethanole extract of propolis
DE3565535D1 (en) Process for the preparation of optically active 1,4-dihydropyridines
ATE101393T1 (en) PHENANTHRIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEANS FOR CARRYING OUT THE PROCESS.
MY102317A (en) Novel microorganisms and a method for production of glutamic acid using the same.
SU1515606A1 (en) Method of purification and isolation of sodium nitroprusside
FI102973B (en) Process for the preparation of 17-oxosteroids
JPS6410950A (en) Elimination of taste and odor of substance rich in amino acid
Lillich et al. Analysis of the intracellular amino acid pool and proteins from whole cells of Rhizobium japonicum
UA14449A1 (en) Process for preparation of pantocrine
JPS55102389A (en) Novel microorganism
JPS5682095A (en) Purification of fatty acid produced through fermentation process